Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …

Apolipoprotein E (APOE) is a multifunctional protein synthesized and secreted by multiple
mammalian tissues. Although hepatocytes contribute about 75% of the peripheral pool …

Type 2 diabetes mellitus (T2DM) is one of the largest public health problems worldwide.
Insulin resistance-related metabolic dysfunction and chronic hyperglycemia result in …

Despite the known heterogeneity of type 2 diabetes and variable response to glucose
lowering medications, current evidence on optimal treatment is predominantly based on …

Little is known about the genetic determinants of medication use in preventing
cardiometabolic diseases. Using the Finnish nationwide drug purchase registry with follow …

Diabetes mellitus has become one of the most challenging public health problems today.
There are still various deficiencies that remain in existing therapeutic drugs. With increasing …

Metabolic diseases including type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver
disease (NAFLD), and metabolic syndrome (MetS) are alarming health burdens around the …

Type 2 diabetes mellitus (T2D) is a chronic metabolic disease resulting from insulin
resistance and progressively reduced insulin secretion, which leads to impaired glucose …

The prevalence of obesity continues to grow rapidly worldwide, posing many public health
challenges of the 21st century. Obese subjects are at major risk for serious diet-related …